All the Shorts have covered and only 1% of the shares are Short now. There should not be any idle talk about a Short Squeeze with this stock. Buying will be the reason for an increase in the stock price.
Take a look at the Yahoo Finance Maximum Chart for AEZS and you will notice that it traded between $6,900.00 & $4,200.00 a share between 2000 and 2006.
Vemurafenib/Cobimetinib Shows 30% OS Benefit in BRAF-Mutant Melanoma. I am looking for a 1% increase in the share price for each 1% improved overall survival.
najarian_t: I think those who are patient will benefit next year, if not later this year.
wazoo_wazoo_wazoo: I guess we will have to make a point of being patient during the next five weeks that are left in the remainder of this year if we want to benefit.
The Stock Formed a Bullish Descending Triangle Pattern
November 18, 2015
by Casey McCarthy
The stock of Exelixis, Inc. (EXEL) formed a descending triangle with $8.12 target or 41.00% above today’s $5.76 share price. The 7 months triangle pattern indicates low risk for the $1.29 billion company. If the $8.12 price target is reached, the company will be worth $528.90 million more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent. The stock is up 2.22% or $0.12 after the news, hitting $5.76 per share. About 6.29M shares traded hands or 63.38% up from the average. Exelixis, Inc. (NASDAQ:EXEL) has risen 81.94% since April 16, 2015 and is uptrending. It has outperformed by 84.53% the S&P500.
Full article with chart at Google Finance
I have absolutely no sympathy for this Short and he got what he deserves. This is a stock trader betting against a company which is developing cures for cancer, which will hopefully enrich the lives of many people. Micro capitalization biotechnology companies struggle to invent and survive and there are a lot of investors like him that are a pain in the derriere for Longs.
I am saddened to watch mindless people circling the stock and going for the kill of a company that develops cancer drugs in an effort to save lives. Outwardly celebrating making a few dollars for themselves at the expense of others is sick.
I want the stock to increase in price like any XOMA Long stockholder would, but you can't continue lying like this. If you have a link from any source regarding current M&A please copy and paste.
Otherwise shut up you fool and let the stock take its natural course.
hibanx15 started all of this here at this Yahoo Finance Message Board and had better stop before he is reported to the SEC for stock manipulation.
XOMA (XOMA) Uses License Deals and Restructuring to Extend Runway to 2017; Piper Jaffray Remains Neutral
Piper Jaffray reiterated a Neutral rating on XOMA, Ltd. (NASDAQ: XOMA), and raised the price target to $1.80 (from $1.50), following the company's 3Q earnings report. XOMA ended 3Q:15 with $32 million. The company subsequently received $37 million from Novartis for TGF-beta upfront and $5 million from Agenus for an antibody manufacturing facility. XOMA divested its biodefense program to Nanotherapeutics, and reduced headcount by ~50%; thereby reducing near-term cash outflows. These strategic moves have extended the company's runway into 2017. Analyst Edward Tenthoff commented, "XOMA ended 3Q:15 with $32 million and subsequently licensed TGF-beta antibody to Novartis and sold off an antibody manufacturing facility to Agenus, bringing proforma cash to $74 million. Novartis delayed maturity of a $13.5 million loan until 2020, XOMA divested its biodefense program to Nanotherapeutics, and reduced headcount by ~50%; thereby reducing near-term cash outflows. These strategic moves have extended the company's runway into 2017, allowing XOMA to reach proof-of-concept data for XOMA 358 in a congenital hyperinsulinism (HI). We remain Neutral on XOMA, however are increasing our price target to $1.80 from $1.50 by rolling forward our discount period to YE:16."